

Head and Neck Lymphomas in Jos University Teaching Hospital Nigeria: A Five Year Review

Nimkur Lohpon Tonga^{1,*}, Obebe Francis Ameh¹, Okoye Chukwuma¹, John Emmanuel²

¹Department of Otorhinolaryngology, Head and Neck Surgery Jos University Teaching Hospital, Jos, Nigeria

²Department of Surgery, Ear, Nose and Throat (Otorhinolaryngology) Unit Federal Medical Centre Keffi, Keffi, Nigeria

Email address:

nimkurtonga@yahoo.com (Nimkur Lohpon Tonga)

*Corresponding author

To cite this article:

Nimkur Lohpon Tonga, Obebe Francis Ameh, Okoye Chukwuma, John Emmanuel. Head and Neck Lymphomas in Jos University Teaching Hospital Nigeria: A Five Year Review. *International Journal of Clinical Oncology and Cancer Research*. Vol. 8, No. 1, 2023, pp. 1-4.

doi: 10.11648/j.ijcoocr.20230801.11

Received: September 8, 2022; Accepted: October 24, 2022; Published: March 20, 2023

Abstract: *Introduction:* Lymphomas are heterogeneous group of lymphoid tissues traditionally categorized as either Hodgkin's Lymphoma (HL) or Non-Hodgkin's Lymphoma (NHL). The head and neck region is rich in lymphoid tissues, thus a fertile anatomic site for the development of lymphoid proliferative diseases like lymphomas. In the head and neck, malignant lymphomas account for 5% of all malignant neoplasm; Non-Hodgkin's Lymphoma (NHL) is the most common accounting for 75%. The clinical behaviour and manifestations of Lymphomas in the head and neck lack specific characteristics that would enable attribution to a specific lymphoma entity without biopsy and histological evidence. *Materials and Methods:* It is a 5 year retrospective study of confirmed histopathological analysis of head and neck lymphomas from 1st January 2017 to 31st December 2021. Case notes of all histopathologically confirmed head and neck lymphomas were retrieved from the medical records department and also theatre records as supportive data were analysed for age, sex, histological diagnosis, tumour site, duration of symptoms before presentation and treatment modality; and then discussed. *Results:-*The total number of patients seen during the period under review was 1678, 16 patients had histopathologically confirmed lymphomas out of 388 patients with head and neck tumours, thus prevalence of 0.1% and 4.1% of all head and neck tumours. Male to Female ratio of 5:1, age range of 4 to 62 years, mean age of 29 years. Most common tumour site is the cervical region-315; the most frequently seen histological type is the Non Hodgkin's lymphoma (NHL) and the most common duration of symptom before presentation is over 1 year-50%. All patients had chemotherapy as a treatment modality. *Conclusion:* This study reveals the management challenges of the head and neck lymphomas are due to late presentation, financial constraints and ignorance. Health awareness and adequate Health Insurance Policy are needed to cope or mitigate these problems.

Keywords: Lymphoma, Non -Hodgkin's, Hodgkin's, Head and Neck Region

1. Introduction

Lymphoma is a cancer that begins in infection fighting cells of the immune system called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow and other parts of the body. When you have lymphoma, lymphocytes change and grow out of control [16].

Lymphomas are heterogeneous group of neoplasm of the lymphoid tissues traditionally categorized as either Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL), each displaying distinct behavioural, prognostic and

epidemiological characteristics, with varying responses to treatment [1].

The head and neck region is rich in lymphoid tissue, especially Waldeyer's ring, the thyroid, the salivary glands, the oral cavity lymphoid tissues and also several chains of regional lymph nodes. The head and neck region is a fertile anatomic site for the development of lymphoproliferative diseases, in which malignant neoplastic mutations occur in normal lymphoid tissue and give rise to lymphomas. In the head and neck, malignant lymphomas account for 5% of all malignant neoplasms. Non-Hodgkin's lymphoma (NHL) is the most

common (frequent) tumour of the head and neck, accounting for 75% of lymphomas in this anatomic region [2].

Several classifications have been developed over the years for lymphomas. The classification currently in use is that of the World Health Organization (WHO) which is based on the principles of the Revised European-American Classification of Lymphoid Neoplasm (REAL) from 1994 [3]. The latest update of the classification was published in two reviews in Blood in 2016 [4-6]. The subtype of the lymphomas is defined based on the cell of origin: B-cell lymphomas, T-cell and natural killer-cell lymphomas (T/NK-NHL) and HL [7, 8].

HLs frequently involve lymph nodes of the neck and mediastinum, whereas extranodal sites account for only 5% of HLs for example in the tonsils. In contrast, approximately 30% of NHLs show heterogeneous extranodal manifestations, such as in the major salivary glands, paranasal sinuses, mandible, maxilla and Waldeyer’s ring (largely depending and often characteristic for the specific NHL subtype) [9].

The clinical behaviour and manifestations of lymphomas in the head and neck region usually lack specific characteristics that would enable attribution to a specific lymphoma entity without biopsy and histological evidence. In particular, with regard to lymphomas having an aggressive course, immediate histological evidence is crucial for early patient management and thus favorable outcome [10, 11]. This study is carried out to evaluate Head and Neck Lymphomas in our environment, the outcome and proffer better awareness in terms of early presentation and thus better treatment outcome.

2. Materials and Method

This was a five year retrospective study of all confirmed histopathological analysis of head and neck lymphomas from January 1st 2017 to 31st December 2021. Case notes of all histopathologically confirmed head and neck lymphomas were retrieved from medical records of the Jos University Teaching Hospital; Jos, Nigeria; records from the theatre were further retrieved to support the data. The age, sex, histopathological diagnosis, site of primary tumour, duration of symptoms before presentation were extracted and treatment modality were looked at in this study. Data were collected, analysed using SPSS version 26 and presented using frequencies and percentages.

Categorical data were expressed as percentages, mean, mode and standard deviation and simple tables were used to illustrate the data.

3. Results

Demographic Characteristics: The total number of patients seen in the ENT department of the Jos University Teaching Hospital within the period under review was 1678 and 16 patients with histopathologically confirmed lymphomas out of 388 patients with head and neck tumours giving a prevalence of 0.1% and 4.1% of head and neck

tumours. There were 11 males (69%) and 5 females (31%) with M: F ratio of 5:1 and an age range of 4 years to 62 years with a mean age of 29 years, mode of 5years and standard deviation of 20.

Tumour Site Distributions: The neck (cervical) lymph node enlargement recorded the highest number of involvement with 5 patients (31%), followed by Sinonasal tract with 3 patients (18%), oropharynx with 3 patients (18%), the nasopharynx, the mandibular region with 2 patients (12.50%) each and the Oral cavity with 1 patient (6%). Table 2.

Histopathological types: The most common histopathological type was Non-Hodgkin’s lymphoma in 9 patients (56.25%), Hodgkin’s lymphoma in 5 patients (31.25%) and Burkitts lymphoma in 2 patients (12.50%). Table 3.

Duration of symptoms before presentation: Less than 6 months accounted for 2 patients (12.50%), between 6 months to 1 year accounted for 6 patients (37.50%), and greater than 1 year accounted for 8 patients (50%) which mean most of the patients presented late. Table 4.

Treatment modality: All the patients had chemotherapy for treatment after biopsy for histopathological diagnosis. The patient who had Burkitts lymphoma however presented with upper airway obstruction necessitating an emergency tracheostomy before chemotherapy.

Immunohistochemistry was necessary but only one of them could afford it due to financial constraints, this also affected the entire treatment as well. 11 patients (69%) were lost to follow up between 6 months to 30 months after treatment and 2 of the patients who presented late were lost to death.

Table 1. Age distribution of cases.

Age (years)	Frequency	Percentage (%)
1 – 10	5	31
11 – 20	0	0
21 – 30	4	25
31 – 40	1	6
41 – 50	3	19
51 – 60	2	13
61 – 70	1	6
Total	16	100%

Table 2. Tumour Site Distributions.

Tumour Site	Frequency	Percentage (%)
Sinonasal tract	3	19
Nasopharynx	2	12.5
Oropharynx	3	19
Mandible	2	12.5
Cervical	5	31
Oral cavity (hard palate)	1	6
Total	16	100%

Table 3. Histological Types.

Histological Type	Frequency	Percentage (%)
Non Hiolgkim Lymphoma	9	56.25
Hodgkin Lymphoma	5	31.25
Burkitts Lymphoma	2	12.50
Total	16	100%

Table 4. Symptoms Duration before presentation.

Symptoms Duration before presentation	Frequency	Percentage (%)
Less than 6 months	2	12.5
6 months to 1 year	6	37.5
More than 1 year	8	50
Total	16	100

4. Discussion

This study revealed the prevalence of head and neck lymphomas in the Jos University Teaching Hospital, Nigeria to be 0.1% which also represent 4.1% of the head and neck tumours. The prevalence in this study is lower than what was found in the study by Oluwasola et al. of 0.7% of surgical biopsies during a 15 year review of lymphomas in University College Hospital, Ibadan most probably due to the duration of the study and the sample size [12].

There were 11 males (69%) and 5 females (31%) in this study with a Male to Female ratio of M:F=5:1. The male preponderance in this study is similar to that found by Shamloo et al. in a study of head and neck lymphomas in an Iranian population [13].

This study shows that the paediatric age group of 1 to 10 years was the most affected with 5 patients (31%) Table 1, which is in keeping with the findings by Roh et al. in Seoul, South Korea for lymphomas of the Head and Neck in a paediatric population [15].

This study revealed cervical lymph node involvement to be the most common anatomic site (31%) Table 2, though higher but similar to the findings of 23% by Alli et al. in Johannesburg, South Africa in a 20 year review of head and neck lymphomas [14].

The histological type most commonly seen in this study is the Non Hodgkin Lymphoma with 9 patients (56.25%) followed by Hodgkin Lymphoma with 5 patients (31.25%) Table 3.

The duration of symptoms before presentation was commonly late, 8 patients (50%) more than 1 year and followed by 6 patients (37.5%) 6 months to 1 year Table 4, thus reflecting in the treatment outcome.

Majority of the patients 11 (69%) were lost to follow-up, may be they did well after the treatment thus saw no reason to continue the follow-up as is usually the case with patients in our environment mostly due to financial constraint or they would have succumbed to death. This can be mitigated if government can handle health as a pure social responsibility to the people with complete health insurance cover; this will then ensure compliance with early, regular hospital visits and better treatment outcome.

5. Conclusion

This study has revealed some challenges facing clinicians in the management of Head and Neck lymphomas like late presentation, financial constraints most probably due to lack of health insurance policy in our environment and or ignorance. In the light of this, health awareness as regards

this disease and may be Government ensuring the availability of Health Insurance policy for all to ensure proper health coverage for the people in our environment. This will then ensure early presentation and better treatment outcome of this disease condition or any other disease condition.

Conflict of Interest

Authors declared no conflict of interest.

References

- [1] Kleihues P, Stewart BW, editors. 2003 world cancer report. Lymphoma. Lyon: International Agency for Research on Cancer Press, 2003: 237-41.
- [2] Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43 (1): 7-26.
- [3] Mawardi H, Cutler C, Treister N. Medical management update: non-Hodgkin's lymphoma. Oral Surg Oral med Oral Pathol Oral Radiol Oral. J Endod. 2009; 107 (1): 19-33.
- [4] Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. World Health Organization classification of Tumours. Lyon. France: IARC; 2008.
- [5] Swerdlow ST, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127 (20): 2375-90.
- [6] Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127 (20): 2391-405.
- [7] Harris NL, Jaffe ES, Stein H, et al. A revised European American classification of lymphoid neoplasm: a proposal from the international lymphoma study group. Blood. 1994; 84: 1361-92.
- [8] Jaffe ES, Harris NL, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999; 111 (Suppl): 8-12.
- [9] Weber AL, Rahemtullah A, Ferry JA. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. Neuroimaging Clin N Am. 2003; 13: 371-92.
- [10] Sohani AR, Hasserjian RP. Diagnosis of Burkitt lymphoma and related high-grade B-cell neoplasms. Surg Pathol Clin. 2010; 3 (4): 1035-59.
- [11] Toader C, Toader M, Stoica A, Pop G, Oprea A, et al. Tonsillar lymphoma masquerading as obstructive sleep apnea -pediatric case report. Rom J Morphol Embryol. 2016; 57 (2 Suppl): 885-91.
- [12] Oluwasola AO, John AO, Jesse AO, Gabriel OO, et al. A Fifteen-year Review of Lymphomas in a Nigerian Tertiary Healthcare Centre. Journal of Health Population and Nutrition. 2011. 29 (4): 310-316.

- [13] Shamloo N, Ghannadan A, Jafari M, Ahmadi S, Mortazavi H, Baharvand M. Head and lymphoma in an Iranian population. *Iran J Otorhinolarygol.* 2017. 94: 262-267.
- [14] Alli N, Meer S. Head and neck lymphomas: A 20 year review in an oral pathology unit. *Oral Oncol.* 2017. 67: 17-23.
- [15] Roh JL, Huh J, Moon HN. Lymphomas of the head and neck in the paediatric population. *Int J Pediatr Otorhinolaryngol.* 71 (9): 1471-7.
- [16] GOOGLE: <https://www.webmd.com/...>Leukemia and Lymphoma. Lymphoma: Definition, Symptoms, Causes, Diagnosis...> 4 mar 2022.